Get Permission Ali, Mohanty, Prasad, and Das: Effect of baclofen on physiotherapy in the management of spastic cerebral palsy


Introduction

Cerebral palsy (CP) is heterogeneous with different clinical types, comorbidities, brain imaging patterns, causes, and now also heterogeneous underlying genetic variants. Few are solely due to severe hypoxia or ischemia at birth.1 Cerebral palsy incidence is 1.5-2.5 per 1000 live births2, 3 and contributes as the most common cause of the chronic childhood disabilities.4 Most common type of CP is spastic type contributing 70 - 80% of all cases.5 Spasticity can reason for discomfort, stiffness, pain and difficulty in performing physical activities such as washing, dressing, transfers, walking and picking up objects.6 Spasticity can be managed by physical therapy, oral medications, tone inhibiting casts, focal injections and by surgery. Treatment of spasticity with oral medicines can be useful only in selected patients where a generalized reduction in body tone is needed. Baclofen, Tizanidine, Diazepam and Dantrolene are currently permitted for use in patients with spasticity. Medication plan should be devised seeking a balance between improved function, patient satisfaction and possible side effects.7 Baclofen is the oldest and most commonly prescribed drugs in cases of spastic CP. Baclofen has Gaba Amino Butyric Acid (GABA) mediated action. Baclofen is an agonist that has presynaptic and postsynaptic effects on monosynaptic and polysynaptic pathways by binding to GABA B receptors. The most common adverse reaction is transient drowsiness, others are dizziness and weakness. Baclofen should be tapered gradually at higher doses to prevent withdrawal symptoms like hallucinations, seizures and increased spasticity. AAN recommends: There is insufficient evidence to support or refute the use of oral baclofen for the treatment of spasticity or to improve motor function in children with CP.8 There are several studies expressing usefulness of Physiotherapy and Baclofen in CP. However, there are very few studies comparing effectiveness of Physiotherapy and Baclofen in spastic CP. The purpose of the study is to compare result of oral Baclofen and Physiotherapy in spastic cerebral palsy in reducing spasticity in cerebral palsy.

Materials and Methods

This study was performed in the Department of Anatomy and Department of Pediatrics, Banaras Hindu University. All the spastic cerebral palsy patients seeking treatment in outpatient department of Pediatrics, University Hospital, Banaras Hindu University and Kiran Society, Varanasi were enrolled in the study. Patients aged between 2 to 14 years of both sexes; with disorder  in  posture  apparently of cerebral origin started before two years of age, presence of spasticity related with or characterized  by increased tone, exaggerated reflexes, clonus or extensor plantar response, and delayed miles stones of  development which is improving  over time  were included as study population. Those with mix type of cerebral palsy; receiving systemic anti-spasticity medications or had received phenol and/or botulinum toxin type A injections; past surgical intervention that might interfere with; neurodegenerative disorders, ankle joint movement inborn errors of metabolism such as galactosemia, chromosomal abnormality such as Down syndrome, and presence of co morbidity such as epilepsy were excluded from the study. Complete history and clinical examination was done for all enrolled patients.  The written informed consent was taken from parents after explaining possible side effects. Patients  were first assessed with Modified Asworth Scale (MAS) based on muscle tone to determine the extent of spasticity. Then Physician Rating Scale was done to measure joint angle (crouch) specially by standard Goniometer, 46 knee recurvatum, foot contact. Intervention was completed by giving oral baclofen with physiotherapy to reduce spasticity, and uniform intensive rehabilitation protocol was applied which includes sitting balance in specialized sitting chair, prone lying position, range of motion exercise, stretching exercise, activities of daily living (ADL) training. The patients were followed 4 weekly till 24th weeks.

Treatment Interventions

Compliance check was done by confirming from guardian and of empty bottles.

Group A was given physiotherapy 1 hour daily for 5 days a week 

Physiotherapy was taught once and done in residence with supportive exercise chart under supervision of guardian.

Group B received oral baclofen with physiotherapy corresponding to approximately 0.3mg/kg a day in two divided doses has given for 24 weeks.9

Ethical clearance

Ethical clearance has been obtained from the concerned authority to conduct the research work.

Statistical Analysis

Descriptive statistics including Standard Deviation (SD) and mean were obtained for each quantitative variable. Data management and statistical analysis was performed using MS excel. Test statistics was used to analysis the data.

Results

A total of 120 patients were enrolled in the study and were divided in to two treatment groups of 60 each. One Group (Group A) received only physiotherapy while the other group (Group B) received physiotherapy along with oral baclofen. The results of the two treatment protocols were analysed after 6 months of therapy.

The age, sex, weight and height of the patients enrolled are shown in Table 1 .

Table 1

Comparison of age sex,weight and height between two groups

Characteristic Group A (n=60) Group B (n=60) Test of significance, P value
Gender
F 32(53.3%) 26(43.3%) t =1.20,
M 28(46.6%) 34(56.6%) p= 0.27
Age (years) 7.3 ± 3.2 6.8 ± 1.4 t =0.722, p=0.47
Weight (kg) 21.7 ± 7.7 20.7 ±8.6 t =0.617, p=0.54
Height (cm) 116.6 ± 19.5 112.5 ± 20.5 t =1.12, p=0.28

The gender distribution, mean age, weight and height were comparable in the two treatment groups.

Table 2

Effect of physiotherapy on spasticity parameters of cerebral palsy

Pre therapy Number (%) Post therapy Number (%) Chi square value, P value
Modified Ashworth scale
0-1 0(0) 02 (03.3) 78.4, 0.000
2-3 10(16.7) 56 (93.4)
4-5 50 (83.3) 02 (03.3)
Physical rating scale
Knee* 4.44, 0.109
Recurvatum >5 4(6.7) 0(0.0)
Recurvatum <0-5 4(6.7) 6(10.0)
No Recurvatum 52(86.6) 54(90.0)
Angle for crouch gait
Severe 20(33.3) 0(0.0) 26.1, 0.000
Moderate 32(53.3) 40(66.7)
Mild 6(10.0) 14(23.3)
None 2(3.4) 6(10.0)
Foot contact
Toe 50(83.3) 0(0.0) 88.3, 0.000
Toe-heel 10(16.7) 38(63.3)
Flat 0(0.0) 22(36.7)
Heel-toe 0(0.0) 0(0.0)

Effect of physiotherapy on spasticity parameters of cerebral palsy are depicted in Table 2.

There was significant improvement of spasticity after 6 months of physiotherapy as evaluated by modified Ashworth scale, angle for crouch gait, and foot contact. Though there was improvement in the physical rating scale in terms of knee recurvatum, it was not statistically significant.

Table 3

Effect of combined physiotherapy and oral Baclofen on spasticity parameters of cerebral palsy

Pre therapy Number (%) Post therapy Number (%) Chi square value , P value
Modified Ashworth scale
0-1 0(0) 46(76.7) 93.1, 0.000
2-3 8(13.3) 12(20.0)
4-5 52(86.6) 2(3.3)
Physical rating scale
Knee* 2.04, 0.361
Recurvatum >5 2(3.4) 0(0.0)
Recurvatum <0-5 8(13.3) 8(13.3)
No Recurvatum 50(83.3) 52(86.7)
Angle for crouch gait
Severe 14(23.3) 0(0.0) 42.0, 0.000
Moderate 28(46.7) 8(13.3)
Mild 14(23.3) 44(73.4)
None 4(6.7) 8(13.3)
Foot contact
Toe 48(80.0) 0(0.0) 94.5, 0.000
Toe-heel 10(16.7) 8(13.3)
Flat 2(3.3) 48(80.0)
Heel-toe 0(0.0) 4(6.7)

Effect of combined physiotherapy and oral Baclofen on spasticity parameters of cerebral palsy are shown in Table 3.

There was also significant improvement of spasticity after 6 months of combined physiotherapy and oral Baclofen as evaluated by modified Ashworth scale, angle for crouch gait, and foot contact. Though there was improvement in the physical rating scale in terms of knee recurvatum, it was not statistically significant.

Table 4

Comparison of baseline spasticityparameters of the treatment groups.

Baseline Characteristic Group A Number (%) Group B Number (%) Chi square value , P value
Modified Ashworth scale
0-1 0(0) 0(0) 2.89, 0.23
2-3 10(16.7) 8(13.3)
4-5 50 (83.3) 52(86.6)
Physical rating scale
Knee* 2.04, 0.36
Recurvatum >5 4(6.7) 2(3.4)
Recurvatum <0-5 4(6.7) 8(13.3)
No Recurvatum 52(86.6) 50(83.3)
Angle for crouch gait
Severe 20(33.3) 14(23.3) 5.19, 0.15
Moderate 32(53.3) 28(46.7)
Mild 6(10.0) 14(23.3)
None 2(3.4) 4(6.7)
Foot contact
Toe 50(83.3) 48(80.0) 2.04, 0.36
Toe-heel 10(16.7) 10(16.7)
Flat 0(0.0) 2(3.3)
Heel-toe 0(0.0) 0(0.0)

llustrates the pretherapy spasticity parameters of the treatment groups. The Modified Ashworth Scale (MAS) grade, the physician rating scale in terms of knee recurvatum, the angle for crouch gait and foot contact were comparable in both treatment groups as there were no statistical difference in the values of two groups.

Table 5

Comparison of the outcome of the treatment groups.

Spasticity parameters Group A Number (%) Group B Number (%) Chi square value, P value
Modified Ashworth scale
0 – 1 2(3.3) 46(76.7) 69.0, 0.00
2 – 3 56(93.4) 12(20.0)
4 – 5 2(3.3) 2(3.3)
Physical rating scale
Knee 0.323, 0.57
Recurvatum >5 0(0.0) 0(0.0)
Recurvatum <0-5 6(10.0) 8(13.3)
No Recurvatum 54(90.0) 52(86.7)
Angle for crouch gait
Severe 0(0.0) 0(0.0)
Moderate 40(66.7) 8(13.3) 34.0, 0.00
Mild 14(23.3) 44(73.4)
None 6(10.0) 8(13.3)
Foot contact
Toe 0(0.0) 0(0.0) 33.2 , 0.00
Toe-heel 38(63.3) 8(13.3)
Flat 22(36.7) 48(80.0)
heel-toe 0(0.0) 4(6.7)

Comparison of the outcome of the treatment groups are shown in Table 5 . There were significant differences in Modified Ashworth scale, Angle for crouch gait and Foot contact in the Group B receiving both physiotherapy and oral baclofen as compared to physiotherapy alone. Physical rating scale in terms of knee recurvatum was comparable.

The patients receiving baclofen experienced side effects like drowsiness in 18 (30%), increased frequency of urination in 10 (16.6%), weakness in 8 (13.3%), headache, constipation and paresthesia in 4 (6.6%) each. Two (3.3%) each experienced nausea, urticaria, ataxia and behavioural changes.

Discussion

The study was conducted using the most commonly used oral antispastic drugs i.e. Baclofen and Physiotherapy in patients with spastic CP. The result of physiotherapy and oral Baclofen with physiotherapy was compared in patients with spastic CP in terms of diminution of spasticity, progress in range of motion and adverse effect profile. In present study, 120 children with cerebral palsy were divided into two groups (60 physiotherapy and another 60 baclofen with physiotherapy group). At the baseline assessment baclofen with physiotherapy group; 8(13.3%) were MAS grade 3, 36(60.0%) grade 4, 16(26.7%) grade 5. After 6 months, spasticity was significantly decreased; 46(76.7%) children pointed MAS grade 0-1, 12(20.0%) were grade 2-3 and 2(3.3%) grade 4-5. In physiotherapy group; 10(16.7%) were MAS grade 3, 44(73.3%) grade 4, 6(10.0%) grade 5. After 6 months, spasticity also significantly decreased in this group; 2(3.3%) children pointed MAS grade 0-1, 56(93.3%) were grade 2-3 and 2(3.3%) grade 4-5. In this study we obtained that baclofen with physiotherapy group furnish better response in reducing spasticity compared to in the physiotherapy group, regarding physician ratings scale, majority of the severe and moderate angle for crouch gait at baseline in physiotherapy group transformed to moderate and mild angle respectively. However, the baclofen with physiotherapy group received more development, with most of the severe and moderate angle for crouch gait at baseline changed to mild a few to none. In addition, this study confirmed that both Physiotherapy and oral Baclofen with physiotherapy are highly effective agents to combat spasticity in CP. Statistically considerable progress was seen in the mean MAS score at in both the groups. A study on Baclofen in 23 patients with spasticity of spinal origin showed significant improvement in terms of mean change in MAS as compared to placebo.10 A controlled trial of Baclofen showed significant improvement in spasticity in a group of 20 cerebral palsy patients. Baclofen study found significant improvement in active range of motion as compared to placebo.11 A double-blind, randomized cross-over pilot study of oral baclofen versus placebo on fifteen children with spastic or spastic/dystonic quadriplegia scored significantly better on the Goal Attainment Scale with baclofen compared with placebo.12 Furthermore, Changes in knee recurvatum in both groups were not significant. During determining crouch, the patient in the physiotherapy group had at baseline 33.3% severe and 53.3% moderate angle at baseline. But baclofen with physiotherapy baseline scores were 23.3% and 46.6% respectively. Physiotherapy group also show improvement in angle for crouch but baclofen with physiotherapy group change more significantly. In present study maximum children having foot contact with their toes at baseline in physiotherapy group changed to toe-heel contact 38(63.3%) or flat foot 22(36.7%). The children of the baclofen with physiotherapy group also demonstrated a similar change. The change was more noted in the baclofen with physiotherapy group. these finding are similar to Amin et al. 13 Baclofen has been weakly studied in spasticity of cerebral origin with most studies evaluating efficacy in treating spasticity of spinal cord origin. While no studies on the use of baclofen to treat children was found, it is still commonly recommended as a treatment option for children with spasticity. 14, 15 Blocks of intensive therapy can be an alternative to regular dosage of physiotherapy, however, until further studies are conducted, the physiotherapy intervention, intensity, and frequency should be tailored to meet the needs of each individual infant and family.16 Analytical findings of this study showed that combined baclofen and intensive rehabilitation is more beneficial to decrease stiffness and spasm and thereby improving movement in a young child with cerebral palsy.

Conclusion

The study exhibited that elementary abilities and self-care enhanced after physiotherapy with baclofen is effective for reducing generalized spasticity regarding muscle tone and joint angle stiffness and gait improvement in cerebral palsy patients over physiotherapy.

Source of Funding

None.

Conflict of Interest

None.

References

1 

Alastair H. MacLennan Suzanna C. Thompson Jozef Gecz Cerebral palsy: causes, pathways, and the role of genetic variantsAm J Obstet Gynecol201521377988

2 

P Rosenbaum N Paneth A Leviton M Goldstein M Bax D Damiano A report: The definition and classification of Cerebral PalsyDev Med and Child Neurol Suppl2006109814

3 

K.C.K. Kuban Alan Leviton Cerebral PalsyN Engl J Med1994330318895

4 

F Stanley E Blair E Alberman Cerebral Palsies: Epidemiology and Causal PathwaysLondon: Mac Keith2000

5 

M V Johnston R M Kliegman B F Stanton J W St. Geme N F Schor R E Behrman Cerebral Palsy Cerebral Palsy In: Nelson Textbook of PediatricsElsevier SaundersPhiladelphia. McGrawHill, New York201220615

6 

J R Sawyer Palsy Philadelphia : Mosby ElsevierCampbell’s Oper Orthop2007133388

7 

A J Thompson L Jarrett L Lockley J Marsden V L Stevenson Clinical management of spasticityJ Neurol Neurosurg Psychiatry20057645963

8 

E M Goldstein Spasticity management: An overviewJ Child Neurol2001161623

9 

Akmer Mutlu Ayse Livanelioglu Mintaze Kerem Gunel Reliability of Ashworth and Modified Ashworth Scales in Children with Spastic Cerebral PalsyBMC Musculoskeletal Disord20089144

10 

P. Hudgson D. Weightman Baclofen in the Treatment of SpasticityBMJ197145778157

11 

P J Milla A Controlled trial of Baclofen in children with Cerebral PalsyJ Int Med Res19775398405

12 

Adam Scheinberg Kate Hall Lawrence T Lam Stephen O'Flaherty Oral baclofen in children with cerebral palsy: A double-blind cross-over pilot studyJ Paediatr Child Health2006421171520

13 

M R Amin N Saha S Rahman M S Hossain M J Islam M S Islam Efficacy of baclofen in combination with Intensive rehabilitation in spastic Cerebral palsy- a randomized clinical TrialJ Dhaka Med Coll2014231823

14 

J Whyte K Robinson Pharmacologic Management. The practical management of spasticity in children and adultsPhiladelphia: Lea and Febiger1990209

15 

L Stempien D Gaebler-Spira Rehabilitation of children and adults with cerebral palsyPhysical Medicine and Rehabilitation. Philadelphia: WB Saunders1996111345

16 

L Pellegrino Paul H Cerebral palsyChildren with disabilities4th Edn.Brookes publishing499528



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijpns.2020.011


Article Metrics






Article Access statistics

Viewed: 1782

PDF Downloaded: 638